These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30638797)

  • 1. Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90 months of follow-up.
    Chen W; Zhao Y; Xie X; Liu J; Li J; Zhao C; Wang S; Liao X; Shou Q; Zheng M; Saah AJ; Wei L; Qiao Y
    Vaccine; 2019 Feb; 37(6):889-897. PubMed ID: 30638797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up.
    Wei L; Xie X; Liu J; Zhao Y; Chen W; Zhao C; Wang S; Liao X; Shou Q; Qiu Y; Qiao Y; Saah AJ
    Vaccine; 2019 Jun; 37(27):3617-3624. PubMed ID: 30122646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.
    Mugo N; Ansah NA; Marino D; Saah A; Garner EI
    Hum Vaccin Immunother; 2015; 11(6):1323-30. PubMed ID: 25912475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.
    Huh WK; Joura EA; Giuliano AR; Iversen OE; de Andrade RP; Ault KA; Bartholomew D; Cestero RM; Fedrizzi EN; Hirschberg AL; Mayrand MH; Ruiz-Sternberg AM; Stapleton JT; Wiley DJ; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Cuzick J; Garland SM; Kjaer SK; Bautista OM; Haupt R; Moeller E; Ritter M; Roberts CC; Shields C; Luxembourg A
    Lancet; 2017 Nov; 390(10108):2143-2159. PubMed ID: 28886907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety, and immunogenicity of a quadrivalent HPV vaccine in Japanese men: A randomized, Phase 3, placebo-controlled study.
    Mikamo H; Yamagishi Y; Murata S; Yokokawa R; Han SR; Wakana A; Sawata M; Tanaka Y
    Vaccine; 2019 Mar; 37(12):1651-1658. PubMed ID: 30797638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults.
    Moreira ED; Palefsky JM; Giuliano AR; Goldstone S; Aranda C; Jessen H; Hillman RJ; Ferris D; Coutlee F; Vardas E; Marshall JB; Vuocolo S; Haupt RM; Guris D; Garner EI
    Hum Vaccin; 2011 Jul; 7(7):768-75. PubMed ID: 21712645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants.
    Garland SM; Anagani M; Bhatla N; Chatterjee S; Lalwani S; Ross C; Group T; Lin J; Luxembourg A; Walia A; Tu Y
    Hum Vaccin Immunother; 2022 Nov; 18(6):2105067. PubMed ID: 35997582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-hoc analysis of injection-site reactions following vaccination with quadrivalent human papillomavirus vaccine in Japanese female clinical trial participants.
    Murata S; Shirakawa M; Sugawara Y; Shuto M; Sawata M; Tanaka Y
    Papillomavirus Res; 2020 Dec; 10():100205. PubMed ID: 32827835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness on high-grade cervical abnormalities and long-term safety of the quadrivalent human papillomavirus vaccine in Japanese women.
    Sakamoto M; Miyagi E; Sumi Y; Aisaka K; Kuno N; Nagano H; Asahara S; Han SR; Wakana A; Murata S; Sawata M; Tanaka Y
    J Infect Chemother; 2019 Jul; 25(7):520-525. PubMed ID: 30879979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study.
    Huang Z; He J; Su J; Ou Z; Liu G; Fu R; Shou Q; Zheng M; Group T; Luxembourg A; Liao X; Zhang J
    Vaccine; 2021 Jan; 39(4):760-766. PubMed ID: 33239228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM).
    Hidalgo-Tenorio C; Ramírez-Taboada J; Gil-Anguita C; Esquivias J; Omar-Mohamed-Balgahata M; SamPedro A; Lopez-Ruz M; Pasquau J
    AIDS Res Ther; 2017 Jul; 14(1):34. PubMed ID: 28720147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine.
    Levin MJ; Huang S; Moscicki AB; Song LY; Read JS; Meyer WA; Saah AJ; Richardson K; Weinberg A;
    Vaccine; 2017 Mar; 35(13):1712-1720. PubMed ID: 28238631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of the Quadrivalent HPV Vaccine in Preventing Anal ≥ HSILs in a Spanish Population of HIV+ MSM Aged > 26 Years.
    Hidalgo-Tenorio C; Pasquau J; Omar-Mohamed M; Sampedro A; López-Ruz MA; López Hidalgo J; Ramírez-Taboada J
    Viruses; 2021 Jan; 13(2):. PubMed ID: 33498165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women.
    Ruiz-Sternberg ÁM; Moreira ED; Restrepo JA; Lazcano-Ponce E; Cabello R; Silva A; Andrade R; Revollo F; Uscanga S; Victoria A; Guevara AM; Luna J; Plata M; Dominguez CN; Fedrizzi E; Suarez E; Reina JC; Ellison MC; Moeller E; Ritter M; Shields C; Cashat M; Perez G; Luxembourg A
    Papillomavirus Res; 2018 Jun; 5():63-74. PubMed ID: 29269325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
    Goldstone SE; Giuliano AR; Palefsky JM; Lazcano-Ponce E; Penny ME; Cabello RE; Moreira ED; Baraldi E; Jessen H; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Bautista O; Das R; Group T; Luxembourg A; Zhou HJ; Saah A
    Lancet Infect Dis; 2022 Mar; 22(3):413-425. PubMed ID: 34780705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.
    Garland SM; Cheung TH; McNeill S; Petersen LK; Romaguera J; Vazquez-Narvaez J; Bautista O; Shields C; Vuocolo S; Luxembourg A
    Vaccine; 2015 Nov; 33(48):6855-64. PubMed ID: 26411885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of a booster dose of quadrivalent or bivalent HPV vaccine when administered to girls previously vaccinated with two doses of quadrivalent HPV vaccine.
    Gilca V; Sauvageau C; Boulianne N; De Serres G; Crajden M; Ouakki M; Trevisan A; Dionne M
    Hum Vaccin Immunother; 2015; 11(3):732-8. PubMed ID: 25714044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age.
    Moreira ED; Giuliano AR; de Hoon J; Iversen OE; Joura EA; Restrepo J; Van Damme P; Vandermeulen C; Ellison MC; Krick A; Shields C; Heiles B; Luxembourg A
    Hum Vaccin Immunother; 2018 Feb; 14(2):396-403. PubMed ID: 29211620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV viral suppression results in higher antibody responses in HIV-positive women vaccinated with the quadrivalent human papillomavirus vaccine.
    Money DM; Moses E; Blitz S; Vandriel SM; Lipsky N; Walmsley SL; Loutfy M; Trottier S; Smaill F; Yudin MH; Klein M; Harris M; Cohen J; Wobeser W; Bitnun A; Lapointe N; Samson L; Brophy J; Karatzios C; Ogilvie G; Coutlée F; Raboud J;
    Vaccine; 2016 Sep; 34(40):4799-806. PubMed ID: 27544584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27-45 years.
    Maldonado I; Plata M; Gonzalez M; Correa A; Nossa C; Giuliano AR; Joura EA; Ferenczy A; Ronnett BM; Stoler MH; Jin Zhou H; Joshi A; Das R; Bautista O; Group T; Luxembourg A; Saah A; Buchwald UK
    Hum Vaccin Immunother; 2022 Nov; 18(5):2078626. PubMed ID: 35853188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.